Baidu
map

CLIN CANCER RES:放射性诺模图术前预测膀胱癌淋巴结转移

2017-11-28 MedSci MedSci原创

CLIN CANCER RES近期发表了一篇文章,研究放射性诺模图在膀胱癌淋巴结转移术前诊断中的应用。

CLIN CANCER RES近期发表了一篇文章,研究放射性诺模图在膀胱癌淋巴结转移术前诊断中的应用。

研究共纳入了118例膀胱癌患者,患者分为训练集(n=80)和验证集(n=38)。每名患者均收集动脉期CT图像的放射特征。在验证集中构建放射性特征。联合独立危险因素,使用多因素回归模型构建诺模图。在训练集评估诺模图效力并在验证集中进行验证。最后联合训练集和验证集进行决策曲线分析评估诺模图的临床应用。研究结果表明,由9个淋巴结相关特征构成的诺莫图达到了一定的预测效力。诺模图联合放射性特征和CT报告的淋巴结状态在训练集和验证集中均表现出了良好的校准和区分功能。决策曲线表明该诺莫图具有临床应用意义。该诺模图还在CT报告的淋巴结阴性亚组中具有良好的鉴别功能。

文章最后认为,诺模图是一种非侵入性的术前预测工具,与放射性特征和CT报告的淋巴结状态一起可以有效预测前列腺癌患者淋巴结转移情况。需要进一步的多中心验证试验为其临床应用提供高等级证据。

原始出处:
Shaoxu Wu,Junjiong Zheng,et al.A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer.CLIN CANCER RES.November 2017 doi:10.1158/1078-0432.CCR-17-1510

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=268595, encodeId=983e2685954d, content=值得进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Dec 11 12:45:41 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293011, encodeId=fa15129301167, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302511, encodeId=6bd3130251161, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463979, encodeId=9cea14639e9d5, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265386, encodeId=9a0c26538682, content=不错的.学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Nov 29 19:13:35 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
    2017-12-11 虈亣靌

    值得进一步研究

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=268595, encodeId=983e2685954d, content=值得进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Dec 11 12:45:41 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293011, encodeId=fa15129301167, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302511, encodeId=6bd3130251161, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463979, encodeId=9cea14639e9d5, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265386, encodeId=9a0c26538682, content=不错的.学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Nov 29 19:13:35 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
    2017-11-30 sodoo
  3. [GetPortalCommentsPageByObjectIdResponse(id=268595, encodeId=983e2685954d, content=值得进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Dec 11 12:45:41 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293011, encodeId=fa15129301167, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302511, encodeId=6bd3130251161, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463979, encodeId=9cea14639e9d5, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265386, encodeId=9a0c26538682, content=不错的.学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Nov 29 19:13:35 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=268595, encodeId=983e2685954d, content=值得进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Dec 11 12:45:41 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293011, encodeId=fa15129301167, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302511, encodeId=6bd3130251161, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463979, encodeId=9cea14639e9d5, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265386, encodeId=9a0c26538682, content=不错的.学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Nov 29 19:13:35 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=268595, encodeId=983e2685954d, content=值得进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Dec 11 12:45:41 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293011, encodeId=fa15129301167, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302511, encodeId=6bd3130251161, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463979, encodeId=9cea14639e9d5, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Thu Nov 30 00:50:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265386, encodeId=9a0c26538682, content=不错的.学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Nov 29 19:13:35 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
    2017-11-29 虈亣靌

    不错的.学习了!谢谢分享!

    0

相关资讯

J Urol:一种检测膀胱癌的灵敏度比尿细胞学更高的90分钟一体化尿液分析方法。

尽管敏感性不佳,但尿细胞学通常作为膀胱镜检查诊断膀胱癌的辅助手段。本研究的目标是开发一种非侵入性,快速检测膀胱癌的分子诊断测试,它比尿细胞学检测的灵敏度更高,同时又能够保持足够的特异性。

Oncotarget:COL3A1过表达或与膀胱癌预后差相关。

在此研究中,研究者构建了加权基因共表达网络,以鉴定与BCa(n = 93)进展相关的基因模块。在重要模块(R(2)= 0.48)中,共鉴定出103个网络hub基因,其中4个同时是蛋白质 - 蛋白质相互作用网络中的中枢节点。

Cell Mol Life Sci:蛋白激酶D抑制剂CRT0066101通过在G2 / M阻断细胞周期抑制膀胱癌细胞体外和异种移植物的生长。

在本研究中,作者发现CRT0066101在体外抑制了四种膀胱癌细胞系的增殖和迁移,并且证明CRT0066101能够阻断膀胱癌小鼠侧腹异种移植模型中肿瘤的生长。

CLIN CANCER RES:PI3K通路作为膀胱癌的潜在治疗靶点

超过40%的膀胱尿路上皮癌中出现PI3K通路激活。CLIN CANCER RES近期发表了一篇文章,研究靶向PI3K通路药物的治疗潜力及耐药机制。

Oncotarget:膀胱癌侵袭的蛋白质组学分析:靶向EIF3D进行治疗干预。

此研究重点分析了膀胱癌发生侵袭的蛋白质组学变化,旨在更好地了解疾病病理生理学和对药物靶标的鉴定。研究者通过高离析液相色谱联合串联质谱对非肌层浸润性膀胱癌(NMIBC,pTa期)和肌层浸润性膀胱癌(MIBC,阶pT2 +期)患者的组织标本进行了分析。

BJU Int:根治性膀胱切除术(RC)患者住院时间太短与再入院和出院后并发症的风险增加有关?

本研究的目的是评估根治性膀胱切除术(RC)后早期出院的患者是否与再入院和出院后并发症的风险增加有关。

Baidu
map
Baidu
map
Baidu
map